Therapeutic Area: Oncology

Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes

Chu Y, et al.
April 2023
Authors and Affiliates
Yaya Chu 1 , Jordan Milner 1 , Margaret Lamb 2,3 , Elena Maryamchik 4,5 , Olivia Rigot 1 , Janet Ayello 1 , Lauren Harrison 1 , Rosemarie Shaw 1 , Gregory K Behbehani 6 , Elaine R Mardis 3,7 , Katherine Miller 7 , Lakshmi Prakruthi Rao Venkata 7 , Hsiaochi Chang 6 , Dean Lee 2,3 , Elana Rosenthal 1 , Stephan Kadauke 4 , Nancy Bunin 5,8 , Julie-An Talano 9 , Bryon Johnson 10 , Yongping Wang 4,5 , Mitchell S Cairo 1,11,12,13; 1 Department of Pediatrics, New York Medical College, Valhalla, New York, USA. 2 Department of Hematology/Oncology/Bone Marrow Transplant, Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio, USA. 3 Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA. 4 Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 5 Perlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 6 Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, Ohio, USA. 7 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA. 8 Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 9 Department of Pediatrics, Hematology/Oncology and BMT, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 10 Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 11 Department of Medicine, New York Medical College, Valhalla, New York, USA. 12 Department of Microbiology, Immunology, and Pathology, New York Medical College, Valhalla, New York, USA. 13 Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York, USA.

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer

Chow A, et al.
April 2023
immuneAccess
Authors and Affiliates
Andrew Chow 1 , Fathema Z Uddin 2 , Michael Liu 2 , Anton Dobrin 3 , Barzin Y Nabet 4 , Levi Mangarin 5 , Yonit Lavin 2 , Hira Rizvi 6 , Sam E Tischfield 7 , Alvaro Quintanal-Villalonga 2 , Joseph M Chan 2 , Nisargbhai Shah 2 , Viola Allaj 2 , Parvathy Manoj 2 , Marissa Mattar 8 , Maximiliano Meneses 8 , Rebecca Landau 8 , Mariana Ward 8 , Amanda Kulick 8 , Charlene Kwong 8 , Matthew Wierzbicki 8 , Jessica Yavner 8 , Jacklynn Egger 6 , Shweta S Chavan 7 , Abigail Farillas 2 , Aliya Holland 5 , Harsha Sridhar 2 , Metamia Ciampricotti 2 , Daniel Hirschhorn 5 , Xiangnan Guan 4 , Allison L Richards 7 , Glenn Heller 9 , Jorge Mansilla-Soto 10 , Michel Sadelain 11 , Christopher A Klebanoff 12 , Matthew D Hellmann 13 , Triparna Sen 2 , Elisa de Stanchina 8 , Jedd D Wolchok 14 , Taha Merghoub 15 , Charles M Rudin 16; 1 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: chowa1@mskcc.org. 2 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Department of Oncology Biomarker Development, Genentech, South San Francisco, CA, USA. 5 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 11 Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 14 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tmerghoub@med.cornell.edu. 16 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rudinc@mskcc.org.

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.

Phillips TJ, et al.
Blood Advances
April 2023
Authors and Affiliates
Tycel J. Phillips, MD1 David Bond, MD2 Radihka Takiar, MD3 Karson Kump, PhD3 Malalthi Kandarpa, PhD3 Philip Boonstra, PhD3 Tera Lynn Mayer, NP3 Victoria Nachar, Pharm D3 Ryan A. Wilcox, MD, PhD3 Shannon A. Carty, MD3 Yasmin H. Karimi, MD3 Zaneta Nikolovska-Coleska, PhD3 Mark S. Kaminski, MD3 Alex F. Herrera, MD1 Kami Maddocks, MD2 Leslie Popplewell, MD1 Alexey V. Danilov, MD1 1. City of Hope National Medical Center, Duarte, CA, 91010, 2. The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, 3. The University of Michigan Rogel Cancer Center, Ann Arbor, MI 48105

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Cassaday RD, et al.
March 2023
Authors and Affiliates
Ryan D. Cassadaya,b, Lucas C. Zarlinga, Kelsey-Leigh A. Garciaa, Olga Sala-Torrab, Philip A. Stevensonc, Christen H. Martinoa,b, Yajuan J. Liud, Min Fangb,d, Mary-Elizabeth M. Percivala,b, Anna B. Halperna,b, Pamela S.Beckera,b,e, Vivian G. Oehlera,b, Andrei R. Shustova, Jason P. Coopera,b, Johnnie J. Orozcoa,b,Paul C. Hendriea,b, Roland B. Waltera,b , Jerald P. Radicha,b, Lorinda A. Somaf and Elihu H. Esteya,b aDepartment of Medicine, University of Washington, Seattle, WA, USA; bClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; cClinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; dDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; eDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA; fDepartment of Pathology, City of Hope National Medical Center, Duarte,CA, USA

Combination IFNβ and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity

Zheng H, et al.
February 2023
immuneAccess
Authors and Affiliates
Hong Zheng 1, Xiaoqing Yu 2, Mohammed L Ibrahim 3, Dana Foresman 3, Mengyu Xie 4, Joseph O Johnson 2, Theresa A Boyle 2, Brian Ruffell 2, Bradford A Perez 5, Scott J Antonia 6, Neal Ready 7, Andreas N Saltos 8, Mark J Cantwell 9, Amer A Beg 10; 1 Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 2 Moffitt Cancer Center, Tampa, FL, United States. 3 Moffitt Cancer Center, Tampa, United States. 4 Moffitt Cancer Center, United States. 5 H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 6 Duke University School of Medicine, Durham, NC, United States. 7 Duke Medical Center, Durham, NC, United States. 8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States. 9 Memgen, Inc., Houston, TX, United States. 10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Thieblemont C, et al.
Journal of Clinical Oncology
December 2022
Authors and Affiliates
Catherine Thieblemont, MD, PhD1; Tycel Phillips, MD2; Herve Ghesquieres, MD, PhD3; Chan Y. Cheah, MBBS, DMSc4,5;Michael Roost Clausen, MD, PhD6; David Cunningham, MD7; Young Rok Do, MD, PhD8; Tatyana Feldman, MD9;Robin Gasiorowski,MBBS, PhD10; Wojciech Jurczak, MD, PhD11; Tae Min Kim, MD, PhD12; David John Lewis, MD13;Marjolein van der Poel, MD, PhD14; Michelle Limei Poon, MD15; Mariana Cota Stirner, MD, PhD16; Nurgul Kilavuz, MSc17;Christopher Chiu, PhD17; Menghui Chen, PhD17; Mariana Sacchi, MD17; Brian Elliott, MD17; Tahamtan Ahmadi, MD, PhD17;Martin Hutchings, MD, PhD18; and Pieternella J. Lugtenburg, MD, PhD19 1 Assistance Publique & Hopitaux de Paris (APHP), H ˆ opital Saint-Louis, ˆHemato-oncologie, Universit ´ e de Paris, Paris, France ´ 2 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 3 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Benite, ´ France 4 Sir Charles Gairdner Hospital, Perth, Australia 5 Division of Internal Medicine, Medical School, University of Western Australia, Perth, Australia 6 Vejle Hospital, Vejle, Denmark 7 The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom 8 Keimyung University Dongsan Medical Center, Daegu, Republic of Korea 9 Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ 10Concord Hospital, University of Sydney, Sydney, Australia 11MSC National Research Institute of Oncology, Krakow, Poland ´ 12 Seoul National University Hospital, Seoul, Republic of Korea 13 University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, United Kingdom 14 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/ LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands 15 National University Hospital, Singapore 16 AbbVie, North Chicago, IL 17 Genmab, Princeton, NJ 18 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 19 On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, the Netherlands

Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML

Fujii S, et al.
Molecular Therapy — Oncolytics
December 2022
Authors and Affiliates
Shin-ichiro Fujii 1,2,10, Toyotaka Kawamata 3,10, Kanako Shimizu 1,10, Jun Nakabayashi 4, Satoru Yamasaki 1, Tomonori Iyoda 1, Jun Shinga 1, Hiroshi Nakazato 1, An Sanpei 1, Masami Kawamura 1, Shogo Ueda 1, Jan Dörrie 5, Svetlana Mojsov 6, Madhav V. Dhodapkar 7, Michihiro Hidaka 8, Masanori Nojima 9, Fumitaka Nagamura 9, Shigemi Yoshida 2, Toshio Goto 2, and Arinobu Tojo 3; 1 Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Science (IMS), 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, Japan 2 Program for Drug Discovery and Medical Technology Platforms, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, Japan 3 Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo (IMSUT): Minato-ku, Tokyo, Japan 4 Department of Mathematics, Tokyo Medical and Dental University, Ichikawa, Chiba, Japan 5 Department of Dermatology, Universitätsklinikum Erlangen, Erlangen, Germany 6 The Rockefeller University, New York, NY, USA 7Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, USA 8Department of Hematology/Oncology, National Hospital Organization Kumamoto Medical Center, Clinical Laboratory: Kumamoto, Kumamoto, Japan 9Center for Translational Research, The Institute of Medical Science, The University of Tokyo (IMSUT), Minato-ku, Tokyo, Japan

Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection

Win TS, et al.
JCI
November 2022
Authors and Affiliates
Thet Su Win 1,2, William J Crisler 1, Beatrice Dyring-Andersen 1, Rachel Lopdrup 2, Jessica E Teague 1, Qian Zhan 1, Victor Barrera 3, Shannan Ho Sui 3, Sotirios Tasigiorgos 2, Naoka Murakami 4, Anil Chandraker 4, Stefan G Tullius 5, Bohdan Pomahac 2, Leonardo V Riella 4, Rachael A Clark 1; 1 Department of Dermatology and. 2 Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3 Bioinformatics Core, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 4 Schuster Transplantation Research Center and. 5 Division of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment

Akhave N, et al.
Lung Cancer
November 2022
Authors and Affiliates
Neal Akhave 1, Jiexin Zhang 2, Erin Bayley 3, Meredith Frank 1, Shin-Heng Chiou 4, Carmen Behrens 5, Runzhe Chen 1, Xin Hu 6, Edwin Roger Parra 7, Won-Chul Lee 6, Stephen Swisher 3, Luisa Solis 7, Annikka Weissferdt 8, Cesar Moran 8, Neda Kalhor 8, Jianhua Zhang 6, Paul Scheet 8, Ara A Vaporciyan 3, Boris Sepesi 3, Don L Gibbons 1, John V Heymach 1, Jack J Lee 9, Ignacio I Wistuba 5, P Andrew Futreal 6, Jianjun Zhang 10, Junya Fujimoto 11, Alexandre Reuben 12; 1 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 2 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 3 Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 4 Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 195 Little Albany St, New Brunswick, NJ 08901, USA. 5 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 6 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 7 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 8 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA; Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 9 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. 10 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. Electronic address: jzhang20@mdanderson.org. 11 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. Electronic address: jfujimot@mdanderson.org. 12 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA.